1. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence.
- Author
-
Barbas Bernardos G, Herranz Amo F, González San Segundo C, Caño Velasco J, Subirá Ríos D, Moralejo Gárate M, Mayor de Castro J, Aragón Chamizo J, and Hernández Fernández C
- Subjects
- Aged, Humans, Male, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local mortality, Prostate-Specific Antigen blood, Prostatectomy, Prostatic Neoplasms blood, Prostatic Neoplasms mortality, Retrospective Studies, Risk Factors, Salvage Therapy, Survival Analysis, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery
- Abstract
Objective: Survival analysis of patients with prostate cancer (PCa) with adverse prognostic factors (APF) treated with radical prostatectomy (RP) and salvage radiotherapy (SRT) after biochemical recurrence (BR) or biochemical persistence (BP)., Materials and Methods: Retrospective analysis of 446 patients with at least one of the following APF: Gleason score ≥8, pathologic stage ≥pT3 and/or positive surgical margins. BR criteria used was PSA level over 0.4ng/ml. A survival analysis using Kaplan-Meier was performed to compare the different variable categories with log-rank test. In order to identify risk factors for SRT response and cancer specific survival (CSS) we performed univariate and multivariate analyses using Cox regression., Results: Mean follow up: 72 (IQR 27-122) months, mean time to BR: 42 (IQR 20-112) months, mean PSA level at BR: 0.56 (IQR 0.42-0.96). BR was present in 36.3% of the patients. Biochemical response to SRT was observed in 121 (75.7%) patients. Recurrence-free survival (RFS) rates after SRT at 3, 5, 8 and 10years were 95.7%, 92.3%, 87.9%, and 85%; overall survival (OS) rates after 5, 10 and 15years was 95.6%, 86.5% and 73.5%, respectively. CSS rates at 5, 10 and 15years were 99.1%, 98.1% and 96.6%. Only time to BR <24months (HR=2.55, P=.01) was identified as an independent risk factor for RFS after SRT., Conclusions: In these patients, RP only controls the disease in approximately half of the cases. Multimodal sequential treatment (RP+SRT when needed) increases this control, achieving high CSS rates and biochemical control in over 87% of the patients. Patients with time to recurrence >24months responded better to rescue treatment., (Copyright © 2020 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF